Erschienen in:
01.08.2007 | PHASE II STUDIES
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study
verfasst von:
Koji Takeda, Nobuhide Takifuji, Shunichi Negoro, Kiyoyuki Furuse, Shinichiro Nakamura, Yoshiki Takada, Takanobu Hoso, Shinichi Hayasaka, Takashi Nakano, Jun Araki, Hiroshi Senba, Fumiyuki Iwami, Yasufumi Yamaji, Masahiro Fukuoka, Harumichi Ikegami
Erschienen in:
Investigational New Drugs
|
Ausgabe 4/2007
Einloggen, um Zugang zu erhalten
Summary
Purpose: We conducted a multicenter phase II study of amrubicin, a novel 9-aminoanthracycline, to evaluate its efficacy and safety in patients with non-small-cell lung cancer (NSCLC). Patients and methods: Entry requirements included cytologically or histologically proven measurable NSCLC, stage III or IV, no prior therapy, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate organ function. Amrubicin was given by daily intravenous injection at 45 mg/m2/day for three consecutive days, repeated at 3 week intervals. Each patient received at least three treatment cycles. Results: Sixty-two patients were enrolled in this study. Of the 62 registered patients, 60 were eligible and assessable for efficacy, and 59 for toxicity. Overall response rate was 18.3% (95% confidence interval [CI], 9.5 to 30.4%) and median survival time was 8.2 months (95% CI, 6.7 to 10.4 months). Major toxicity was myelosuppression, with incidences of grade 3 or 4 toxicity of 78.0% for neutropenia, 54.2% for leukopenia, 30.5% for anemia, and 28.8% for thrombocytopenia. Non-hematological toxicities with a greater than 50% incidence were anorexia (69.5%), nausea/vomiting (55.9%), and alopecia (75.9%), but were relatively mild, with grade 3 toxicities observed in only one patient each (1.7%). Conclusion: Amrubicin was an active, well-tolerated agent in the treatment of NSCLC.